Sol-Gel Technologies Income from Continuous Operations 2016-2024 | SLGL
Sol-Gel Technologies income from continuous operations from 2016 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Sol-Gel Technologies Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-27 |
| 2022 |
$-15 |
| 2021 |
$3 |
| 2020 |
$-29 |
| 2019 |
$-25 |
| 2018 |
$-33 |
| 2017 |
$-32 |
| 2016 |
$-21 |
| 2015 |
$-10 |
Sol-Gel Technologies Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$-6 |
| 2023-12-31 |
$-5 |
| 2023-09-30 |
$-6 |
| 2023-06-30 |
$-6 |
| 2023-03-31 |
$-11 |
| 2022-12-31 |
$-6 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-0 |
| 2022-03-31 |
$-6 |
| 2021-12-31 |
$14 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$-8 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-6 |
| 2020-09-30 |
$-9 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$-7 |
| 2019-09-30 |
$-7 |
| 2019-06-30 |
$-5 |
| 2019-03-31 |
$-6 |
| 2018-12-31 |
$-13 |
| 2018-09-30 |
$-8 |
| 2018-06-30 |
$-7 |
| 2018-03-31 |
$-6 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$-6 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.020B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
